Skip to main content
Clinical Trials/NCT01709422
NCT01709422
Completed
Phase 4

Efficacy and Safety Profiles of Sedation With Propofol Combined With Intravenous Midazolam and Meperidine Versus Intravenous Midazolam and Meperidine for Ambulatory Endoscopic Retrograde-cholangiopancreatography(ERCP).

Prince of Songkla University1 site in 1 country140 target enrollmentJune 2010

Overview

Phase
Phase 4
Intervention
Propofol
Conditions
Disorders of Gallbladder, Biliary Tract and Pancrease
Sponsor
Prince of Songkla University
Enrollment
140
Locations
1
Primary Endpoint
Procedure Related Time
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to compare efficacy and safety of combination of propofol and midazolam with meperidine versus midazolam and meperidine for ambulatory ERCP

Detailed Description

ERCP is commonly done under sedation with midazolam and meperidine, however some studies showed varying outcomes of this conventional sedation for maintained sedation. Propofol is increasing used for sedation in gastrointestinal procedure owing to its rapid recovery profiles but the complications associated with propofol are not negligible.The investigators prospectively compare the efficacy, induction time, recovery time, patient satisfaction and side effect between propofol based and conventional sedations in patients undergoing ERCP.

Registry
clinicaltrials.gov
Start Date
June 2010
End Date
November 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nisa Netinatsunton

NKC Institute of Gastroenterology and Hepatology

Prince of Songkla University

Eligibility Criteria

Inclusion Criteria

  • . All outpatients aged more than 18 years who were schedule for ERCP -

Exclusion Criteria

  • pregnant woman
  • emergency situation ( i.e. concomitant upper gastrointestinal bleeding, acute cholangitis )
  • American Society of Anesthesiologist ( ASA )Class IV or V
  • respiratory disease,
  • sleep apnea
  • allergy to egg or soybean
  • drug abuse( benzodiazepine, opioid agonist )
  • previous history of failure sedation

Arms & Interventions

Propofol

both midazolam (1mg if aged \<= 70 years or 0.5mg in age \>70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.

Intervention: Propofol

Propofol

both midazolam (1mg if aged \<= 70 years or 0.5mg in age \>70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.

Intervention: Midazolam

Propofol

both midazolam (1mg if aged \<= 70 years or 0.5mg in age \>70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.

Intervention: Meperidine

Conventional

both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.

Intervention: Midazolam

Conventional

both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.

Intervention: Meperidine

Outcomes

Primary Outcomes

Procedure Related Time

Time Frame: participants will be followed for the duration of procedure, an expected average of 2.0 hours ]

(1) induction time ( the time from sedation to scope intubation ), (2) procedure time ( the time from scope intubation to scope withdrawal ) and (3) recovery time ( the time from scope withdrawal to full recovery ).The induction time, procedural time and recovery time were recorded by the nurse in the endoscopy unit.

Secondary Outcomes

  • Cardiovascular Adverse Events.(participants will be followed for the duration of procedure, an expected average of 2.0 hours)

Study Sites (1)

Loading locations...

Similar Trials